Evaluation of Safety and Efficacy of IPL Presets for Cutaneous Lesions

Inclusion Criteria

• •1. Healthy Female/Male, age 21-80
• •2. Fitzpatrick skin type I-V
• •3. Presence of visible textural lesions including but not limited to:
• •1. Lentigines
• •2. Age spots / Telangiectasia (Photoaging treatment)
• •3. Rosacea (Erythematotelangiectatic rosacea and papulopustular rosacea)
• •4. Telangiectasia
• •4. Patients should have at least 3 treatment areas of the following: right cheek, left cheek, forehead, nose, chin, or upper/lower décolletage.
• •5. Able to read, understand and provide written Informed Consent.
• •6. Able and willing to comply with the treatment/follow-up schedule and requirements.
• •7. Willing to have digital photographs taken of all of the treatment areas before, during, and after the treatment.
• •8. Willing to refrain from using any prescription or over-the-counter topical creams used for the treatment of veins or pigmented lesions in the treatment area during the study period.
• •9. Willing to protect and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher in the treatment area, every day for the duration of the study.
• •10. Agree not to undergo any other procedure(s) in the same treatment areas during the study.
• •11. Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, or abstinence) at least 1 month prior to first treatment and throughout the course of the study.